Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables: 2020-2024

Historic Receivables for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $2.1 million.

  • Caribou Biosciences' Receivables rose 10.87% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year decrease of 8.61%. This contributed to the annual value of $2.1 million for FY2024, which is 14.01% down from last year.
  • Latest data reveals that Caribou Biosciences reported Receivables of $2.1 million as of FY2024, which was down 14.01% from $2.4 million recorded in FY2023.
  • Caribou Biosciences' 5-year Receivables high stood at $6.6 million for FY2021, and its period low was $2.1 million during FY2024.
  • In the last 3 years, Caribou Biosciences' Receivables had a median value of $2.4 million in 2023 and averaged $2.3 million.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 73.17% in 2021, then crashed by 63.10% in 2022.
  • Yearly analysis of 5 years shows Caribou Biosciences' Receivables stood at $3.8 million in 2020, then soared by 73.17% to $6.6 million in 2021, then tumbled by 63.10% to $2.4 million in 2022, then fell by 0.61% to $2.4 million in 2023, then dropped by 14.01% to $2.1 million in 2024.